89
Participants
Start Date
December 1, 2025
Primary Completion Date
November 30, 2027
Study Completion Date
December 31, 2027
3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping
All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping
The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
St. Joseph's Healthcare Hamilton, Hamilton
St. Joseph's Healthcare Hamilton
OTHER